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AbstrAct
Objective
To assess the overall effect of delayed antibiotic 
prescribing on average symptom severity for patients 
with respiratory tract infections in the community, and 
to identify any factors modifying this effect.
Design
Systematic review and individual patient data meta-
analysis.
Data sOurces
Cochrane Central Register of Controlled Trials, Ovid 
Medline, Ovid Embase, EBSCO CINAHL Plus, and Web 
of Science.
eligibility criteria fOr stuDy selectiOn
Randomised controlled trials and observational 
cohort studies in a community setting that allowed 
comparison between delayed versus no antibiotic 
prescribing, and delayed versus immediate antibiotic 
prescribing.
Main OutcOMe Measures
The primary outcome was the average symptom 
severity two to four days after the initial consultation 
measured on a seven item scale (ranging from normal 
to as bad as could be). Secondary outcomes were 
duration of illness after the initial consultation, 
complications resulting in admission to hospital or 
death, reconsultation with the same or worsening 
illness, and patient satisfaction rated on a Likert 
scale.
results
Data were obtained from nine randomised controlled 
trials and four observational studies, totalling 
55 682 patients. No difference was found in follow-
up symptom severity (seven point scale) for delayed 
versus immediate antibiotics (adjusted mean 
difference −0.003, 95% confidence interval −0.12 to 
0.11) or delayed versus no antibiotics (0.02, −0.11 
to 0.15). Symptom duration was slightly longer in 
those given delayed versus immediate antibiotics 
(11.4 v 10.9 days), but was similar for delayed versus 
no antibiotics. Complications resulting in hospital 
admission or death were lower with delayed versus 
no antibiotics (odds ratio 0.62, 95% confidence 
interval 0.30 to 1.27) and delayed versus immediate 
antibiotics (0.78, 0.53 to 1.13). A significant 
reduction in reconsultation rates (odds ratio 0.72, 
95% confidence interval 0.60 to 0.87) and an increase 
in patient satisfaction (adjusted mean difference 
0.09, 0.06 to 0.11) were observed in delayed versus 
no antibiotics. The effect of delayed versus immediate 
antibiotics and delayed versus no antibiotics was 
not modified by previous duration of illness, fever, 
comorbidity, or severity of symptoms. Children 
younger than 5 years had a slightly higher follow-up 
symptom severity with delayed antibiotics than with 
immediate antibiotics (adjusted mean difference 
0.10, 95% confidence interval 0.03 to 0.18), but no 
increased severity was found in the older age group.
cOnclusiOns
Delayed antibiotic prescribing is a safe and effective 
strategy for most patients, including those in higher 
risk subgroups. Delayed prescribing was associated 
with similar symptom duration as no antibiotic 
prescribing and is unlikely to lead to poorer symptom 
control than immediate antibiotic prescribing. 
Delayed prescribing could reduce reconsultation 
rates and is unlikely to be associated with an increase 





Antimicrobial resistance is an important public health 
concern.1 2 The burden of antimicrobial resistance has 
increased substantially in recent years,3 and resistance 
to second and third line antibiotics is predicted to 
increase by 70% by 2030 if effective public health 
measures are not implemented.4
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WhAt Is AlreAdy knoWn on thIs topIc
Clinical trials have suggested that delayed prescribing for respiratory tract 
infections is probably safe and effective for most patients
These clinical trials have been underpowered to look at subgroups or harms, and 
might be subject to selection bias
WhAt thIs study Adds
Individual patient data from randomised controlled trials and observational 
studies were used to investigate the effectiveness of delayed antibiotic 
prescribing (compared with no antibiotics or immediate antibiotic prescribing), 
overall and for subgroups such as children and those with comorbidities
Delayed prescribing was associated with similar symptom severity and duration 
as no antibiotics, but patient satisfaction was higher and reconsultation rates 
were lower; the effectiveness did not differ for any of the high risk subgroups
Delayed prescribing is unlikely to lead to poorer symptom control than 
immediate prescribing; older age was associated with increasing benefit on 
symptom severity two to four days after consultation
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Reducing unnecessary and inappropriate use 
of antibiotics is crucial to reduce antimicrobial 
resistance, particularly in primary care where 
antibiotics are most prescribed.2 5 However, antibiotics 
are commonly used to treat acute respiratory tract 
infections, despite studies showing that antibiotics 
have, at best, modest effects.6-9 Guidelines recommend 
that the fewest number of antibiotic courses should 
be prescribed for the shortest period possible.10 11 
However, in the United Kingdom and internationally, 
antibiotics are still being overprescribed.12-16 Delayed 
antibiotic prescribing is a useful strategy that can 
be used to help reduce antibiotic use, especially 
during consultations when patients expect to receive 
an antibiotic prescription.6 A Cochrane review of 
10 trials found that delayed prescribing was as 
effective as immediate prescribing in terms of clinical 
outcomes for cough and cold, but less effective for 
reducing fever, pain, and malaise in some studies, 
and with lower antibiotic use.9 However, the review 
noted a high level of heterogeneity between studies 
that made combining them in a traditional meta-
analysis difficult, and did not allow sufficient power 
for the examination of subgroups of participants or 
complications.
These problems can be addressed in part by 
evidence synthesis using raw individual level data 
from relevant studies.17 18 Therefore, we conducted 
a collaborative individual patient data (IPD) meta-
analysis of randomised controlled trials (RCTs) and 
observational cohort studies to determine the clinical 
effectiveness of a delayed prescribing strategy on 
outcomes for respiratory tract infection, overall and for 
key subgroups of people.
Methods
Protocol and registration
The systematic review and IPD meta-analysis 
were performed according to the published study 
protocol that was registered with PROSPERO 
(CRD42018079400) and was reported in line with 
PRISMA-IPD (preferred reporting items for systematic 
reviews and meta-analysis of individual participant 
data).19 20
eligibility criteria
We included all observational cohort studies and RCTs 
in a community setting that had a delayed antibiotic 
prescribing strategy (prescribed an antibiotic but 
advised the patient not to start taking the course 
unless their condition deteriorated or failed to improve 
after a set period), or a watchful waiting approach 
(observation for a set period to allow spontaneous 
symptom resolution before antibiotic prescription). 
Included studies also had a comparator group (no 
antibiotic prescription or immediate prescription). We 
excluded studies on antibiotic prescribing that were 
not RCTs or observational cohorts (eg, cross sectional, 
case-control, or survey studies), and studies on 
patients in hospital.
study identification and selection
Two researchers (HH and TB) searched the Cochrane 
Central Register of Controlled Trials, Ovid Medline, 
Ovid Embase, EBSCO CINAHL Plus, and Web of Science 
to identify eligible quantitative studies (observational 
cohort studies and RCTs). For observational studies, 
these searches were undertaken from inception to 
23 October 2017. For RCTs, we updated the searches 
undertaken in the most recent Cochrane review, and 
searched from 26 May 2017 to 9 November 2017. 
We searched the International Standard Randomised 
Controlled Trial Number Registry, performed additional 
searches through Google, reviewed reference lists 
of identified papers, and contacted collaborators to 
identify any additional relevant studies. No language 
restrictions were reported. The full search strategy is 
available in the protocol.19 Searches were rerun on 8 
October 2020 but no additional eligible studies were 
identified.
Two reviewers (HH and TB) independently screened 
titles and abstracts to determine inclusion criteria. 
Both reviewers independently assessed the full text of 
potentially relevant studies and determined eligibility. 
Discrepancies were resolved through discussion with a 
third reviewer (BS).
Data collection processes
IPD were requested from the chief investigator for each 
eligible trial and observational study, initially by email 
and if no response was received after two emails by 
letter or telephone call. Once data had been received 
from the original authors, a complete database of all 
study data was prepared in Stata (version 15).21 TB and 
HH performed internal consistency checks against the 
published data to ensure the published analysis could 
be replicated. While the protocol contained a provision 
to contact study authors about any discrepancies, this 
did not prove necessary.
Data relating to the general characteristics of the 
study were extracted, such as study design, country, 
setting, type of respiratory tract infection, average age, 
and funding source. We requested all the variables that 
had been collected in the individual studies from the 
authors and received the full datasets. These variables 
were used in the observational studies to calculate the 
propensity score.
The IPD dataset included baseline data on 
prescribing strategy, age (0-4, 5-15, 16-65, and >65 
years), fever at baseline consultation (greater than or 
less than 37.5ºC), previous duration of illness (above 
or below the median for each study), baseline severity 
of symptoms (average severity across all symptoms 
being above or below the median of each study), sex, 
smoking status (smoker or non-smoker), and lung 
disease (asthma, coronary obstructive pulmonary 
disease, or any other lung disease). Patients were 
classified as having a comorbidity if they had any of 
the chronic conditions (eg, heart disease, diabetes) 
for which data were collected in the original study. 
Follow-up data included symptom diaries (if collected) 
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or days of illness determined by telephone interview, 
complications resulting in admission to hospital or 
death, reconsultation with same or worsening illness, 
and patient satisfaction.
risk of bias assessment for included studies
Two reviewers (HH and BS; TB and BS) independently 
assessed the risk of bias of each included study. RCTs 
were assessed using the Cochrane risk of bias tool 
for allocation bias (random sequence generation, 
allocation concealment, baseline imbalance), depar-
tures from intended interventions (participant and 
study personnel blinding, deviations from intended 
interventions, and analysis in groups to which they 
were randomised), attrition bias and appropriate 
methods to account for missing data, detection bias 
(blinding of outcome assessors), and selective outcome 
reporting.22 RCTs were considered to have a high risk 
of bias if scored as such in more than one of the six 
domains.
We assessed observational cohort studies using 
the ROBINS-I (risk of bias in non-randomised studies 
of interventions) tool for bias due to confounding, 
selection bias, bias due to deviations from intended 
intervention, and bias due to missing data and 
selective reporting.23 Observational cohort studies 
were considered to have a high risk of bias if judged 
to be at serious or critical risk of bias in at least one of 
the domains.
specification of outcome measures
The primary outcome of interest was the average 
symptom severity two to four days after the initial 
consultation. Symptom severity was measured on a 
seven item scale (0-6: normal, very little problem, 
slight problem, moderately bad, bad, very bad, 
as bad as could be).24 Secondary outcomes were 
duration of illness after the initial consultation, 
complications resulting in admission to hospital or 
death, reconsultation with the same or worsening 
illness, and patient satisfaction rated on a Likert scale. 
Reconsultation and complications (defined as hospital 
admission or death) were defined as binary outcomes 
(yes or no). Patient satisfaction data were rescaled 
to a four point scale to allow comparison across 
studies.25
synthesis methods
Study and patient level characteristics were described 
for all studies that contributed IPD. We performed 
a one stage IPD meta-analysis to obtain summary 
estimates and 95% confidence intervals for delayed 
antibiotic prescribing (compared with no antibiotic 
prescribing or immediate antibiotic prescribing) for 
each outcome measure.18 26 The one stage approach 
combines all the data in a single meta-analysis based 
on a suitable regression model, with a random effect 
to account for individual studies. We used a linear 
regression to model the severity of symptoms and 
patient satisfaction, a count model to assess the 
duration of illness, and a logistic regression model to 
assess complications and reconsultation. All models 
controlled for baseline severity of illness, age, and 
condition (acute sore throat, cough or chest infection, 
otalgia or otitis media, or upper respiratory tract 
infection), and study type (RCT or observational). 
All participants were included as randomised and 
the primary analysis was of complete cases (without 
imputation for missing data).27
We used inverse probability weighting by propensity 
score analysis to adjust for baseline factor imbalance 
on measured covariates (such as age, sex, comorbid 
health conditions, and signs and symptoms at baseline 
consultation) in observational studies.28-30 Propensity 
scores based on covariates associated with any of 
the outcomes were derived for each observational 
study. We checked balance by using standardised 
mean differences and the appendix figures show 
the results. Propensity scores were also calculated 
for the RCTs by using the probability of randomised 
intervention given baseline covariates.31 An inverse 
probability of treatment weighting regression was 
carried out for the combined observational and RCT 
data to obtain a pooled estimate of treatment effect. 
We assessed heterogeneity across studies with the 
I2 statistic (tested by Higgins I2 test).22 Substantial 
statistical heterogeneity was considered to be present 
if the I2 statistic was greater than 50% and reasons for 
heterogeneity were explored.22
We repeated each model after including an intera-
ction term between antibiotic prescribing strategy and 
subgroup characteristic to obtain summary estimates 
of the subgroup effects (interactions) of interest, 
which compared differential effects of interventions 
across the outcomes. The prespecified subgroups of 
interest were previous duration of illness (above or 
below median for the condition), age (<16, 16-64, 
>65 years), fever at baseline consultation (>37.5°C), 
comorbid conditions including lung comorbidity (such 
as asthma or chronic obstructive pulmonary disease), 
and severity of symptoms at baseline consultation.
We conducted several sensitivity analyses. All 
analyses were repeated using a two stage approach: 
IPD for each study were first analysed separately and 
then meta-analysed by using random effects models.18 
We performed a two stage meta-analysis of extracted 
study level data from RCTs that did not contribute 
to the IPD to obtain summary estimates of effects of 
delayed antibiotic prescribing that combined IPD and 
non-IPD RCT studies, and to assess IPD availability 
bias.32 This process was not possible for observational 
studies because papers did not control consistently 
for the same confounding factors. Further sensitivity 
analyses included repeating the analyses after 
excluding studies with high risk of bias, and repeating 
subgroup analyses with age, fever, and baseline 
severity treated as continuous variables. All meta-
analyses were undertaken with Stata software (version 
15)21 and statistical significance was considered at the 
5% level.
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certainty of evidence per outcome
We used the five GRADE (grading of recommenda tions 
assessment, development and evaluation) considera-
tions (study limitations, consistency of effect, impre-
cision, indirectness, and publication bias) to assess the 
quality of the evidence for our analysis of the primary 
outcomes.33
Patient and public involvement
Two patient and public involvement team members 
(JB and KS) were involved in determining the research 
question, defining outcome measures, study design, 
and implementation. They attended all study meetings 
and are coauthors on this publication. We also shared 
our research findings with a patient and public 
involvement panel, allowing them to feedback to us 
their interpretation of the evidence and how general 
practitioners might more effectively communicate this 
information to patients. In the absence of published 
minimum clinically important differences for the 
outcomes considered in this study, it was particularly 
helpful to discuss their interpretation as to whether the 
differences observed represented a meaningful change. 
This feedback helped to inform our interpretation of 
the findings.
results
study selection and iPD obtained
We sought IPD from 22 eligible studies (14 RCTs 
and eight observational studies), totalling 59 705 
participants (fig 1).6 34-49 IPD were obtained from 
13 studies (nine RCTs, four observational studies; 
table 1), totalling 55 682 participants. We were 
unable to obtain data from nine eligible studies 
because of no response (n=6), researchers moving 
on (n=2), or no response after initial agreement 
(n=1).50-58
study characteristics
Each study included between 129 and 28 856 
participants (median 557, interquartile range 316-
2690). Participants belonged to a delayed antibiotic 
prescription group and an immediate or no antibiotic 
prescription group. Studies were conducted in the UK, 
the United States, New Zealand, Spain, and one study 
used data from multiple European studies. Most studies 
Randomised controlled trials Observational studies
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fig 1 | PrisMa (preferred reporting items for systematic reviews and meta-analysis) flowchart for randomised controlled trials and observational 
studies on delayed antibiotic prescribing
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were conducted in primary care settings (n=11/13). 
Other settings included a paediatric emergency depart-
ment (n=1) and paediatric clinic (n=1). Mean age of 
study participants ranged from 2.7 to 51.7 years. Six, 
four, and three studies examined all age groups, adult 
populations only, and paediatric populations only, 
respectively. One study focused on the common cold, 
two studies each assessed sore throat and cough, three 
focused on acute otitis media, and seven included 
more than one respiratory tract infection. Eleven out 
of 13 studies (84.6%) reported symptom severity and 
complication outcomes, 12 studies (92.3%) reported 
data on symptom duration and reconsultation, and 
eight studies (61.5%) reported patient satisfaction. 
Length of follow-up was 28-30 days.
Eligible studies that did not contribute IPD data (five 
trials and four observational studies) were generally 
smaller, based on younger populations, and had a 
higher proportion focused on acute otitis media and 
sore throat than IPD studies (table 2). Aggregate data 
were available for 930 patients from five RCTs that did 
not contribute IPD.
The mean age of IPD study participants was 38.7 
years (table 3). Patients in the delayed antibiotics 
group were younger than those prescribed immediate 
antibiotics. A lower proportion of patients in the 
delayed antibiotic group had high baseline severity, 
longer previous duration of illness, fever at baseline, 
or lung disease compared with those in the immediate 
antibiotics group (table 3).
iPD integrity and risk of bias
For all included IPD, we were able to replicate aggregate 
results that were reported in each of the associated 
publications. Each individual study contributing IPD 
was deemed low or moderate risk of bias (fig 2), except 
for two RCTs that were judged to be high risk of bias 
on two domains. We also assessed the risk of bias of 
studies that did not contribute IPD. These studies were 
judged to have potentially high (n=6) or unclear (n=2) 
risk of bias (fig 2), and were more likely to be at risk of 
selection bias but also more likely to have been low risk 
of bias with respect to blinding.
Mean symptom severity two to four days after 
consultation
One stage random effects IPD meta-analysis of 
individual RCTs and observational studies combined 
found that, overall, there was no significant difference 
in symptom severity between delayed antibiotics 
and no antibiotics (mean difference on seven point 
scale −0.003, 95% confidence interval −0.12 to 0.11; 
seven studies, 3907 participants; table 4, fig 3). No 
significant difference was found in symptom severity 
between delayed and immediate antibiotics (0.02, 
−0.11 to 0.15; eight studies, 3752 participants; table 
4, fig 3). Consistent results were obtained using a two 
stage approach.
subgroup effects
None of the prespecified subgroup variables modified 
the effectiveness of delayed antibiotic prescribing 
relative to no antibiotics (table 5). We found a signifi-
cant overall interaction effect of age on the effectiveness 
of delayed relative to immediate antibiotic prescribing 
(mean difference −0.10, 95% confidence interval 
−0.17 to −0.03). Children younger than 5 years had a 
slightly higher follow-up symptom severity score two 
to four days after consultation with delayed versus 
immediate antibiotics (0.10, 0.03 to 0.18), whereas no 
significant difference was found in severity between 
delayed and immediate antibiotics for other age groups 
(table 5).
secondary outcomes
Time to symptom resolution was longer with 
delayed (11.4 days) than immediate antibiotics 
(10.9 days; hazard ratio 1.04, 95% confidence 
interval 1.01 to 1.08). Reconsultation rates 
were lower with delayed (13%) than with no 
antibiotics (17%; odds ratio 0.72, 95% confidence 
interval 0.60 to 0.87), but were not statistically 
significantly different for delayed (16%) versus 
immediate antibiotics (22%; odds ratio 0.95, 95% 
confidence interval 0.74 to 1.22). Complications 
resulting in hospital admission or death were lower 
with delayed than with no antibiotics (odds ratio 
0.62, 95% confidence interval 0.30 to 1.27) and 
lower in delayed than immediate antibiotics (0.78, 
0.53 to 1.13), but neither result was statistically 
significant. Patient satisfaction was higher with 
delayed (3.04 points) than no antibiotics (2.96), 
but by a small difference (mean difference 0.09, 
95% confidence interval 0.06 to 0.11; table 4).
Quality of evidence across studies
Based on GRADE, the overall quality of the evidence 
for all outcomes in the IPD dataset was judged as 
moderate, apart from patient satisfaction which was 
low. Table 6 provides a full evidence profile. Two RCTs 
were deemed higher risk because of lack of blinding 
and allocation concealment, which lowered the rating 
for risk of bias to serious. However, consistent effects 
across RCTs suggest results are likely to be unbiased. 
Observational studies were considered high quality 
table 2 | comparison of included and excluded study characteristics in individual patient 
data (iPD)
eligible study characteristics
no (%) of studies
included in iPD excluded from iPD
Population source
Primary care 11 (84.6) 3 (33.3)
Emergency department 1 (7.7) 2 (22.2)
Paediatric office (USA) 1 (7.7) 4 (44.4)
condition
Common cold 1 (7.7) 0 (0.0)
Acute otitis media 3 (23.1) 4 (44.4)
Sore throat 2 (15.4) 4 (44.4)
Cough 2 (15.4) 2 (22.2)
Respiratory tract infection 7 (53.8) 0 (0.0)
antibiotic group
None 12 (92.3) 2 (22.2)
Immediate 11 (84.6) 7 (77.8)
Delayed 12 (92.3) 7 (77.8)
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and achieved balance on potential covariates, but were 
downrated because residual confounding could not be 
ruled out.
sensitivity analyses
One stage versus two stage IPD analysis—consistent 
results were observed for analyses using a two stage 
approach. We found no significant difference in 
symptom severity between delayed and no antibiotics 
(mean difference 0.04, 95% confidence interval −0.12 
to 0.20) or between delayed and immediate antibiotics 
(0.06, −0.05 to 0.17).
Exploring heterogeneity—additional sensitivity 
analyses explored the effect of heterogeneity across 
studies. For symptom severity analyses, heterogeneity 
was found within the RCTs (I2=65%), and also between 
observational studies and RCTs (P<0.005, I2=68%), for 
delayed versus no antibiotics. The forest plots clearly 
showed that the results for Little (2014) were different 
from the other included studies, perhaps because it 
was the only study to test several delayed strategies 
in a single trial. When data from the Little study were 
excluded from the analyses, the heterogeneity within 
the RCTs was reduced (I2=0%), and also the overall 
heterogeneity between observational studies and RCTs 
was reduced (P=0.25, I2=0%). The results remained 
consistent with the main analysis (no significant 
difference in treatment effect). We did not observe 
any important variability for analyses that explored 
delayed versus immediate antibiotic comparison 
(heterogeneity between observational studies and 
RCTs; P=0.02, I2=24%).
Subgroup analyses with continuous variables—when 
we replaced dichotomised variables with a continuous 
variable for each subgroup, the subgroup results did 
not change. One exception was that patients with 
lower baseline severity had lower follow-up symptom 
severity with delayed versus immediate antibiotics 






































































































































































































































fig 2 | risk of bias for randomised controlled trials (using the cochrane risk of bias tool) and observation studies  
(risk of bias in non-randomised studies of interventions (rObins-i) tool). bold studies contributed to individual 
patient data
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Including data from studies that did not provide 
IPD—we carried out a further sensitivity analysis 
that included aggregate data from published 
estimates of studies that did not provide IPD. 
This sensitivity analysis compared the effect of 
immediate antibiotic prescribing with delayed 
antibiotic prescribing. We observed a stronger 
effect favouring immediate antibiotics for symptom 
severity (mean difference 0.95, 95% confidence 
interval 0.71 to 1.18) when including aggregate 
data, particularly the 1991 study by El-Daher, 
compared with IPD only analysis (0.09, −0.01 to 
0.18; fig 4).
Patient and public involvement
We approached our patient and public involvement 
panel of 10 people with a history of respiratory tract 
infections to discuss these results as they emerged. 
They agreed that the results were reassuring and did 
not suggest a meaningful benefit to taking antibiotics. 
They suggested that the way in which delayed 
prescribing is communicated to patients is important. 
They felt that some patients might not easily assess 
and gauge the severity or nature of their symptoms 
and would need clear guidance to determine whether 
they needed to take antibiotics. Almost all contributors 
emphasised that general practitioners need to 
Observational studies
  Francis et al 2012
  Hay et al 2016
  Little et al 2013
Subgroup: I2=0%
Randomised controlled trials
  Little et al 2005
  Little et al 2014
  Mas-Dalmau et al 2021
  De la Poza Abad et al 2016
Subgroup: I2=59.7%
Heterogeneity between groups: P=0.00
Overall: I2=67.8%
-0.11 (-0.27 to 0.05)
-0.09 (-0.28 to 0.10)
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fig 3 | unadjusted association between treatment group and symptom severity two to four days after consultation for 
delayed versus no antibiotics, and delayed versus immediate antibiotics. Weights are from random effects model
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be better at explaining the self-limiting nature of 
respiratory tract infections and the harmful effects of 
inappropriate use of antibiotics, using examples or 
pictures where necessary to relate to people and ensure 
a clear, simple, and effective message is delivered to 
patients. Qualitative studies of patients support these 
observations of our patient and public involvement 
collaborators.59
discussion
We used individual level data from 13 RCTs and 
observational cohort studies (55 682 patients) to 
assess the clinical effectiveness of delayed antibiotic 
prescribing in patients with respiratory tract infections 
in the community setting. Overall, our findings suggest 
delayed antibiotic prescribing is just as effective as 
no antibiotics for all clinical outcomes, but increa-
sed patient satisfaction and reduced reconsultation 
and complication rates. The reasons for reduced 
reconsultation rates are unclear, but one suggestion 
is that if a prescription is delayed, by the time the 
antibiotic course has finished, symptoms will have had 
more time to settle and so reconsultation is less likely; 
or it could be that secondary opportunistic bacterial 
infections that start later after an initial viral illness are 
more effectively managed by the later start of a delayed 
prescription. The second suggestion is supported by 
findings from the large GRACE trial; one of the groups 
that reported beneficial effects for antibiotics were 
people for whom evidence was found of coinfection 
with viruses and bacterial pathogens.60
Delayed antibiotics resulted in longer duration of 
symptoms than immediate antibiotics, but were as 
effective for the remaining clinical outcomes. The 
literature suggests that delayed prescribing could 
also reduce antibiotic use by patients compared with 
immediate antibiotics by 23-75%.48 61 62 Consistent 
results were obtained in subgroups often considered 
to be at higher risk, which suggests that delayed 
prescribing is unlikely to lead to poorer symptom 
control than immediate antibiotics. In children 
younger than 5 years and in those with higher symptom 
scores at baseline, we found statistically significant 
differences in the symptom severity scores two to four 
days after consultation. However, the mean differences 
were only 0.11 points higher on a scale from 0 to 6 (the 
table 5 | effect of antibiotic prescribing strategy subgroup variable interactions on mean symptom severity score two to 
four days after consultation for delayed versus no antibiotics, and delayed versus immediate antibiotics
subgroup
no of  
studies




adjusted* mean  
difference (95% ci)
Delayed v no antibiotics
Previous duration
 Median and above 6 1835
0.05 (−0.23 to 0.34) 0.70
0.008 (−0.21 to 0.23)
 Below median 1589 0.03 (−0.22 to 0.28)
Age (years)
 0-4 9 749
0.11 (−0.02 to 0.24) 0.11
−0.20 (−0.24 to −0.15)
 5-15 637 0.12 (0.07 to 0.16)
 16-64 2153 −0.03 (−0.14 to 0.08)
 >65 368 0.07 (−0.36 to 0.51)
Fever
 ≥37.5°C 8 1436
0.01 (−0.16 to 0.18) 0.88
−0.03 (−0.15 to 0.09)
 <37.5°C 2211 −0.02 (−0.19 to 0.16)
Comorbidity
 Any lung disease 9 438
0.14 (−0.05 to 0.34) 0.15
0.15 (−0.12 to 0.42)
 No lung disease 2598 −0.01 (−0.15 to 0.13)
Baseline severity
 Median and above 9 1972
−0.05 (−0.28 to 0.19) 0.69
−0.09 (−0.31 to 0.13)
 Below median 1935 −0.14 (−0.33 to 0.04)
Delayed v immediate antibiotics
Previous duration
 Median and above 6 1516 −0.07 (−0.41 to 0.27) 0.68 −0.04 (−0.38 to 0.29) Below median 1526 0.02 (−0.17 to 0.21)
Age (years)
 0-4 9 729
−0.10 (−0.17 to −0.03) 0.005†
0.10 (0.03 to 0.18)
 5-15 548 0.09 (−0.11 to 0.30)
 16-64 2107 −0.09 (−0.27 to 0.09)
 >65 366 −0.19 (−0.62 to 0.25)
Fever
 ≥37.5°C 8 1765 −0.05 (−0.32 to 0.23) 0.80 −0.01 (−0.42 to 0.40) <37.5°C 1662 0.03 (−0.06 to 0.11)
Comorbidity
 Any lung disease 9 483 0.01 (−0.16 to 0.19) 0.87 0.13 (−0.27 to 0.53) No lung disease 2554 0.12 (−0.14 to 0.38)
Baseline severity
 Median and above 9 2286 0.35 (−0.23 to 0.93) 0.24 0.10 (−0.57 to 0.77) Below median 1466 −0.27 (−0.34 to −0.19)
*Adjusted for baseline severity, age, and condition.
†Statistically significant interaction term.
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equivalent of 1 in 10 participants rating symptoms 
one point different; for example, as moderately bad 
rather than a slight problem). This finding suggests 
that while the effect might be statistically significant, 
these differences are not clinically significant, and our 
patient and public involvement panel did not feel that 
they were likely to be meaningful to patients.
strengths and limitations
This large study examined the clinical effectiveness of 
the delayed antibiotic prescribing strategy. Strengths 
include the ability to control for baseline severity, 
to assess the quality of the studies based on the full 
dataset, to explore heterogeneity across studies, and to 
include results obtained from RCTs and observational 
studies. Selection bias associated with trials can limit 
perceived external validity, therefore a strength of this 
study was the ability to include observational data. 
Therefore, the external validity was improved and 
the impact of delayed antibiotic prescribing could be 
assessed in a clinical trial and a real world setting.63
The studies included in the IPD comprised 93% of the 
population from all eligible studies. The observational 
studies that did not provide data tended to be smaller 
studies. The trials for which IPD were not available but 
that were included in a sensitivity analysis were older 
studies (dating from 1991 or earlier). Therefore, the 
difference between the results of the primary analysis 
table 6 | evidence profiles based on graDe (grading of recommendations assessment, development and evaluation) assessment




certainty assessment no of participants
adjusted*  
estimate (95% ci) Quality importance
risk of 







Delayed v no antibiotics
Symptom severity
 4 RCT Serious† Not serious‡ Not serious Not serious§ None 484 815 0.09 (−0.10 to 0.28) Moderate Critical
 3 OS Serious¶ Not serious Not serious Not serious** None 2231 377 −0.10 (−0.12 to −0.08) Low Critical
 7 RCT+OS Serious Not serious Not serious Not serious§ None 2715 1192 −0.003 (−0.12 to 0.11) Moderate Critical
Time to complete symptom resolution (days)
 5 RCT Serious† Not serious‡ Not serious Not serious§ None 540 647 1.04 (0.95 to 1.13) Moderate Important
 3 OS Serious¶ Not serious Not serious Not serious** None 2551 476 0.98 (0.94 to 1.01) Low Important
 8 RCT+OS Serious Not serious Not serious Not serious§ None 3091 1123 1.00 (0.82 to 1.23) Moderate Important
Reconsultation (%)
 5 RCT Serious† Not serious‡ Not serious Not serious§ None 509 611 0.92 (0.67 to 1.26) Moderate Important
 4 OS Serious¶ Not serious Not serious Not serious** None 15 723 5290 0.54 (0.49 to 0.60) Low Important
 9 RCT+OS Serious Not serious Not serious Not serious§ None 16 232 5901 0.72 (0.60 to 0.87) Moderate Important
Complication (hospital admission or death; %)
 6 RCT Serious† Not serious‡ Not serious Not serious§ None 431 530 0.35 (0.07 to 1.92) Moderate Important
 4 OS Serious¶ Not serious Not serious Not serious** None 15 933 5297 0.60 (0.28 to 1.43) Low Important
 10 RCT+OS Serious Not serious Not serious Not serious§ None 16 364 5827 0.62 (0.30 to 1.27) Moderate Important
Patient satisfaction score
 5 RCT Serious† Not serious‡ Not serious Not serious§ None 433 520 0.06 (−0.03 to 0.16) Moderate Important
 1 OS Serious¶ NA Not serious Not serious** None 1001 154 0.10 (−0.03 to 0.23) Low Important
 6 RCT+OS Serious Not serious Not serious Not serious§ None 1434 674 0.09 (0.06 to 0.11) Moderate Important
Delayed v immediate antibiotics
Symptom severity
 5 RCT Serious† Not serious Not serious Not serious None 606 674 0.11 (−0.004 to 0.22) Moderate Critical
 3 OS Serious Not serious Not serious Not serious None 2093 377 −0.12 (−0.33 to 0.07) Low Critical
 8 RCT+OS Serious Not serious Not serious Not serious None 2699 1053 0.02 (−0.11 to 0.15) Moderate Critical
Time to complete symptom resolution (days)
 7 RCT Serious Serious‡ Not serious Not serious None 876 962 1.14 (1.06 to 1.22) Low Important
 3 OS Serious Not serious Not serious Not serious None 2399 480 1.02 (0.97 to 1.07) Low Important
 10 RCT+OS Serious Not serious Not serious Not serious None 3275 1442 1.04 (1.01 to 1.08) Low Important
Reconsultation (%)
 6 RCT Serious Not serious Not serious Not serious†† None 796 865 1.29 (0.84 to 1.99) Moderate Important
 4 OS Serious Serious‡ Not serious Not serious None 21 634 5292 0.70 (0.66 to 0.75) Low Important
 10 RCT+OS Serious Not serious Not serious Not serious None 22 430 6157 0.95 (0.74 to 1.22) Moderate Important
Complication (hospital admission or death; %)
 3 RCT Serious Not serious Not serious Not serious†† None 650 719 1.25 (0.38 to 4.16) Moderate Important
 4 OS Serious Not serious Not serious Not serious None 21 721 5298 0.22 (0.19 to 0.27) Low Important
 7 RCT+OS Serious Not serious Not serious Not serious None 22 371 6017 0.78 (0.53 to 1.13) Moderate Important
Patient satisfaction score
 5 RCT Serious Serious‡ Not serious Not serious None 563 649 −0.13 (−0.31 to 0.05) Low Important
 1 OS Serious NA Not serious Not serious None 1180 156 −0.06 (−0.18 to 0.05) Low Important
 6 RCT+OS Serious Serious Not serious Not serious None 1743 805 −0.12 (−0.26 to 0.03) Low Important
Adjusted estimate=adjusted coefficient, odds ratio, or relative risk; NA=not applicable; OS=observational studies; RCT=randomised controlled trials.
*Adjusted for baseline severity, age, and condition.
†Most RCTs here were not blinded. However, results were not considered biased because similar evidence obtained for blinded studies and observational studies.
‡Statistical but not important heterogeneity.
§Confidence intervals exclude important benefits and harms.
¶Balance achieved for key covariates but residual confounding is still possible.
**Large enough sample size and the 95% confidence interval excludes no effect.
††Wide confidence intervals but not downgraded because overall same conclusion.
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and the sensitivity analysis might be because the trials 
that did provide IPD are more likely to be relevant to 
modern patient populations. This difference might 
also be partly due to eligible trials that did not 
contribute IPD being based on younger populations, 
as highlighted in our subgroup analyses which showed 
that children younger than 5 years might benefit more 
from immediate antibiotics; however, this is unlikely 
because the size of the interaction was statistically 
significant but not clinically important. The studies 
that were included with aggregate data only were also 
at high risk of selection, attrition, and other biases. In 
particular, the study by El-Daher favoured immediate 
antibiotics over delayed antibiotics. The Cochrane 
review on this topic suggests that the El-Daher study 
was one of the less methodologically sound of the 
included studies. However, the El-Daher study is also 
the only one undertaken in a lower income setting9 
and it is not clear whether the results of the IPD would 
generalise to that population. The illness spectrum 
in a lower income setting might be different, and the 
previous probability of more serious infection could 
be higher as could the risk of complications. Different 
organisms might be more prevalent and underlying 
comorbid conditions (such as tuberculosis) could lead 
to a different outcome. Delayed access to reassessment 
or secondary care in the event of deterioration might 
also be an important factor.64 Further research is 
needed in low to middle income countries to determine 
whether delayed antibiotic prescribing would be a safe 
and effective strategy in such settings.
A further limitation relates to the statistical 
power. Not all outcomes were collected in all 
studies. Symptom severity data were not collected 
for all studies, or were only collected for a subset of 
participants in some studies, resulting in a smaller 
sample size for the outcome analysis. This outcome 
was based on diary data and those who completed 
and returned diaries might not be representative 
of all study participants, which could also impact 
generalisability. However, previously published esti-
mates from included studies suggest that those who 
completed diaries had broadly similar characteristics 
to all recruited participants.65 66 Power was also low 
for the comparisons involving complications because 
this outcome is extremely rare, even in a dataset as 
large as the one we compiled. However, this extensive 
dataset enabled us to include large numbers of 
participants when analysing outcomes—even the 
smallest comparison contained 2108 participants—
and the rarity of severe complications should be 
reassuring.
Delayed prescribing is one of several strategies that 
might help to safely reduce inappropriate antibiotic 
prescribing and consumption. Other strategies, such as 
point of care diagnostic testing, patient decision aids, 
and specific training for health professionals, might 
also be helpful alone or in combination with delayed 
prescribing.67 68 However, none of the studies included 
in our IPD evaluated these strategies, which means we 
can only draw conclusions about delayed prescribing 
when used in isolation rather than in combination 
with other approaches that might be deployed in a 
primary care setting.
Looking across all the outcomes we included, we 
found a tendency for the treatment effect estimates from 
observational studies to be in the opposite direction 
from those of RCTs. This finding could be because of 
residual confounding (eg, use of other, or known or 
unmeasured covariates such as patient presence and 
compliance) in observational studies, differences in 
how delayed prescribing is implemented in real life 
versus RCTs, and varying time periods. However, the 
overall heterogeneity estimates for the combined RCT 
and observational study analyses were not high or 
could be explained by individual studies at higher risk 
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fig 4 | Difference in mean symptom severity two to four days after consultation; aggregate meta-analysis including 
studies that did not provide individual patient data (iPD)
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of bias. We recognise that our pooled effect estimates 
were influenced by observational studies because these 
contributed large numbers of individual participants 
to the overall pooled dataset. The magnitude of the 
pooled treatment effect needs to be interpreted with 
caution because, while propensity scores were used to 
control for measured confounding, there might still be 
residual confounding from unmeasured confounders.
conclusions and implications
Delayed prescribing appears to be a safe and effective 
antibiotic strategy for most patients, including 
those in higher risk subgroups. Compared with 
a no prescription approach, delayed prescribing 
probably reduces reconsultation rates, and therefore 
the workload of general practitioners, with slightly 
higher levels of patient satisfaction. Compared with 
immediate antibiotics, delayed prescribing does 
not result in higher complication rates (if anything, 
they are lower) and it does not significantly decrease 
patient satisfaction. Delayed prescribing could be used 
as a standalone interventional approach, but it might 
also be a way of resolving mismatched expectations 
between clinician and patient.
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